{"prompt": "['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', '3.0 OBJECTIVES AND ENDPOINTS', 'Table 1', 'Study Objectives and Enppoints', 'Objectives', 'Enppoints', 'Efficacy', 'Primary Efficacy', 'To investigate the efficacy of two concentrations', 'Proportion of subjects with VIIS \"treatment', 'of topically applied TMB-001 as a treatment for', 'success\" (VIIS-50), which is defined as a 50% or', 'congenital ichthyosis (CI) of either the autosomal', 'greater decrease in VIIS scaling score relative to', 'recessive congenital ichthyosis-lamellar ichthyosis', 'Baseline at Visit 6 (EOS) calculated using the sum', '(ARCI-LI) or RXLI subtypes.', \"of the scores for 'VIIS body areas' that have a\", 'Baseline score > 3.', 'Key Secondary Efficacy', 'IGA scores, dichotomized to \"treatment success\"', 'or \"treatment failure\" where \"treatment success\" is', 'defined as at least a 2-grade decrease in severity', 'score relative to Baseline at Visit 6 (EOS).', 'Other Secondary Efficacy', 'Time to achieve VIIS-50 (> 50% reduction in VIIS', 'scaling score for body sites that had a Baseline', 'score > 3) that is maintained at the next', 'observation.', 'Changes in VIIS scaling score relative to Baseline', 'at Visit 4 and Visit 5.', 'Proportion of subjects with IGA \"treatment', 'success\" at Visit 4, Visit 5, and Visit 6 (EOS).', 'Proportion of subjects with an IGA score of 0 or 1', 'representing \"cleared\" or \"almost cleared\" at', 'Visit 6 (EOS).', 'Changes in percent BSA relative to Baseline with', 'CI in the Treatment/Assessment Areas at Visit 3,', 'Visit 4, Visit 5, and Visit 6 (EOS).', 'Change from Baseline in I-NRS score at Visit 6', '(EOS).', 'Proportion of subjects with I-NRS \"treatment', 'success\" where \"success\" is defined as at least a', '4-point reduction in I-NRS relative to Baseline at', 'Visit 6 (EOS).', 'Change in DLQI from Baseline to Visit 6 (EOS).', '19']['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', 'Objectives', 'Endpoints', 'Safety', 'Safety', 'To investigate the safety of topically applied', 'Incidence (severity and causality) of any local and', 'TMB-001.', 'systemic AEs.', 'Number of subjects with presence (and severity) at', 'each time point of the following LSRs:', 'burning/stinging, erythema, erosions, and edema.', 'Changes from Baseline in vital signs at Visit 6', '(EOS).', 'Changes from Baseline in clinical laboratory test', 'results (chemistry, hematology, and urinalysis) at', 'Visit 6 (EOS).', 'Abbreviations: AE = adverse event; ARCI-LI = autosomal recessive congenital ichthyosis-lamellar ichthyosis;', 'BSA = body surface area; CI = congenital ichthyosis; DLQI = Dermatology Life Quality Index; EOS = End of', \"Study; IGA = Investigator's Global Assessment; I-NRS = Itch-Numeric Rating Scale; LSR = local skin\", 'reaction; RXLI = recessive X-linked ichthyosis; VIIS = Visual Index for Ichthyosis Severity.', '20']['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', '4.0 STUDY DESIGN', '4.1', 'Overall Design', 'This is a randomized, parallel, double-blind, vehicle-controlled study to evaluate the safety and', 'efficacy of two concentrations of topical TMB-001 for the treatment of CI in subjects with either', 'the ARCI-LI or RXLI subtypes.', 'Approximately 10 study centers from United States of America and Australia are expected to', 'participate in this global study.', 'The duration of treatment will be 12 weeks.', 'Each subject will participate in the study for up to 24 weeks (including up to a 90-day Screening', 'period).', '4.1.1', 'Treatment Groups', 'Eligible subjects will be randomized (1:1:1) to 1 of 3 treatment groups:', '1. TMB-001 Ointment, 0.05%, bid', '2. TMB-001 Ointment, 0.1%, bid', '3. Vehicle Ointment (Control), 0%, bid', '4.1.2', 'Treatment/Assessment. Areas', 'Treatment/Assessment Areas are defined as:', '4.1.2.1', 'Treatment Area', 'The area of the entire body with active CI where the study medication will be applied (the entire', 'body except for the hands, face, neck, scalp and genitalia are possible treatment areas.)', '4.1.2.2', 'The Visual Index for Ichthyosis Severity (VIIS) Assessment Areas', 'The primary efficacy assessment will be performed using the Visual Index for Ichthyosis Severity', '(VIIS). Four VIIS Assessment Areas will be defined as described below and will be further', 'described using color illustrations in the Investigator Study Binder:', '(a) the upper back from the posterior axillary fold to the other encompassing the T1-T10,', '(b) the upper arm (excluding elbow), left or right,', '(c) the shin/lower leg (the portion below the proximal aspect of the knee cap), left or right', '(d) dorsal foot (left or right).', '21']\n\n###\n\n", "completion": "END"}